These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22307209)

  • 1. Single dose NTBC-treatment of hereditary tyrosinemia type I.
    Schlune A; Thimm E; Herebian D; Spiekerkoetter U
    J Inherit Metab Dis; 2012 Sep; 35(5):831-6. PubMed ID: 22307209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
    Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
    J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?
    El-Karaksy H; Rashed M; El-Sayed R; El-Raziky M; El-Koofy N; El-Hawary M; Al-Dirbashi O
    Eur J Pediatr; 2010 Jun; 169(6):689-93. PubMed ID: 19882170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosinemia type I: Case series with response to treatment to NTBC.
    Shah I; Shah F
    Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory monitoring of patients with hereditary tyrosinemia type I.
    Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
    Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
    Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis.
    Cansever MS; Aktuğlu-Zeybek AC; Erim FB
    Talanta; 2010 Mar; 80(5):1846-8. PubMed ID: 20152421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
    Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
    Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.
    Herebian D; Spiekerkötter U; Lamshöft M; Thimm E; Laryea M; Mayatepek E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(14-15):1453-9. PubMed ID: 19345648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
    Sander J; Janzen N; Terhardt M; Sander S; Gökcay G; Demirkol M; Ozer I; Peter M; Das AM
    Clin Chim Acta; 2011 Jan; 412(1-2):134-8. PubMed ID: 20883679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.
    Lock EA; Gaskin P; Ellis MK; Provan WM; Robinson M; Smith LL; Prisbylla MP; Mutter LC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):439-47. PubMed ID: 8975769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended.
    D'Eufemia P; Celli M; Tetti M; Finocchiaro R
    Eur J Pediatr; 2011 Jun; 170(6):819. PubMed ID: 21340489
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
    Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients.
    Davit-Spraul A; Romdhane H; Poggi-Bach J
    J Chromatogr Sci; 2012 May; 50(5):446-9. PubMed ID: 22511487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.
    Lock EA; Gaskin P; Ellis MK; McLean Provan W; Robinson M; Smith LL
    Toxicology; 2000 Apr; 144(1-3):179-87. PubMed ID: 10781886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.
    Schlump JU; Perot C; Ketteler K; Schiff M; Mayatepek E; Wendel U; Spiekerkoetter U
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S223-5. PubMed ID: 18500574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
    van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
    Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
    J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
    Sundberg J; Wibrand F; Lund AM; Christensen M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.